EUCTR2020-004270-22-IT进行中（未招募）1 期
PHASE II STUDY OF TOTAL MARROW AND LYMPHOID IRRADIATION (TMLI) GIVEN IN COMBINATION WITH CYCLOPHOSPHAMIDE AND ETOPOSIDE (VP-16) AS CONDITIONING FOR ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HIGH-RISK ACUTE LYMPHOCYTIC OR MYELOGENOUS LEUKEMIA - TMLI
IRCCS-A.O.U. SAN MARTINO-IST0 个研究点目标入组 34 人开始时间: 2021年8月17日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 34
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Age =18 to =60 years
- •Karnofsky performance status must be =70%
- •Patients with acute lymphocytic leukemia or acute myelogenous leukemia who are not in first remission or second remission, i.e. after failing induction therapy, or in relapse, or beyond second remission.
- •All candidates for this study must have an HLA (A,B,C,DR) identical sibling who is willing to donate bone marrow or primed blood stem cells, a 10/10 allele matched unrelated donor.
- •Patients must undergo cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm, and an ejection fraction of =50% established by MUGA or echocardiogram.
- •Patients must have a serum creatinine of less than or equal to 1.3 mg/dL or creatinine clearance > 80ml/min.
- •Patients must have bilirubin of less than or equal to 1.5mg/dL and should also have an SGOT and SGPT less than 5 times the upper limit of normal
- •Pulmonary function tests including DLCO will be performed. FEV1and DLCO should be greater than 50% of predicted normal value.
- •The time from the end last induction or re-induction attempt should be greater than or equal to 14 days.
- •All patients must have a psychosocial evaluation prior to transplant as per COH SOP
- •All subjects must have the ability to understand and the willingness to sign a written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients who have received a prior autologous or allogeneic transplant are excluded
- •Uncontrolled inter-current illness including, but not limited to ongoing or active or poorly controlled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, poorly controlled pulmonary disease or psychiatric illness/social situations that would limit compliance with study requirements.
- •Pregnant and lactating women are excluded from this study.
- •Patients who do not agree to practice effective forms of contraception.
- •Patients who received radiation therapy that would exclude them from the use of total body irradiation are ineligible and individual patients who have received prior radiation must be presented to the study PI for eligibility determination.
- •Patients with active 2nd malignancies other than AML, ALL or MDS.
- •Any psychiatric, social or compliance issues that, in the treating physician opinion, will interfere with completion of the transplant treatment and follow up.
研究者
相似试验
招募中
2 期
IMRT-TMLI PIImalignant hematological diseasesJPRN-jRCT1032230247Murofushi Keiko28
已完成
不适用
Phase I trial of Total Marrow and Lymphoid Irradiation Transplantation ConditioningHematologic malignancyJPRN-UMIN000037581Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital9
进行中（未招募）
2 期
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute LeukemiaAcute Myeloid LeukemiaHigh Risk Myelodysplastic SyndromeMyelodysplastic SyndromeAcute Lymphoblastic LeukemiaNCT04262843City of Hope Medical Center33
进行中（未招募）
2 期
Study of Intensity Modulated Total Marrow Irradiation (IM-TMI) in Addition to Fludarabine/Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic SyndromesMyelodysplastic SyndromesAcute Myeloid LeukemiaNCT03121014University of Illinois at Chicago38
招募中
2 期
Evaluation of Lymphatic flow using indocyanine green fluorescence imagingColorectal adenocarcinomaJPRN-jRCTs061210023Kondo Akihiro100